NIH scientists collect clues to improving cancer care from ‘exceptional responders’
A small number of cancer patients respond particularly well to drugs. These so-called “exceptional responders” not only see their tumors shrink with treatment, they also enjoy responses that are unusually long. Understanding of the molecular features of this rare group of patients could guide the development of new strategies for fighting cancer.